



VistaGen® Therapeutics

COMPANY OVERVIEW

<https://ir.vistagen.com/tear-sheet>

RECENT NEWS

[VistaGen Therapeutics Receives European Patent regarding Methods of Production for AV-101](#)

Apr 10 2018, 8:30 AM EDT

[VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder](#)

Apr 5 2018, 8:00 AM EDT

[VistaGen Therapeutics Receives a Notice of Allowance for Another Key U.S. Patent Covering Oral Formulations of AV-101](#)

Mar 19 2018, 10:17 AM EDT

STOCK OVERVIEW

Symbol	VTGN
Exchange	NASDAQ
Shares OS	22,902,615
Market Cap	\$19.47M
Last Price	\$0.85
52-Week Range	\$0.69 - \$2.65

INVESTOR RELATIONS

VistaGen Therapeutics, Inc.

Mark A. McPartland
Vice President, Corporate
Development
T: 1-650-577-3606
markmcp@vistagen.com

KCSA Strategic Communications
Valter Pinto / Allison Soss
T: 1-212-896-1254 / 1-212-896-1267
VistaGen@KCSA.com

MANAGEMENT TEAM

Shawn K. Singh

Chief Executive Officer and Director

H. Ralph Snodgrass, Ph.D.

Founder, President, Chief Scientific Officer
and Director

Mark A. Smith, M.D, Ph.D.

Chief Medical Officer

Jerrold D. Dotson, CPA

Vice President, Chief Financial Officer and
Secretary

Mark A. McPartland

Vice President of Corporate Development

VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue
South San Francisco, CA 94080

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.